Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stok Raporu

Piyasa değeri: US$5.9m

Hoth Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Hoth Therapeutics's earnings are forecast to decline at 32.6% per annum. EPS is expected to grow by 50.6% per annum.

Anahtar bilgiler

-32.6%

Kazanç büyüme oranı

50.6%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi23.7%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme16 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics extends agreement for experimental antibiotic

Jun 18

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

May 05

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Hoth therapeutics signs production agreement for HT-001, Shares up 75%

Dec 31

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:HOTH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026N/A-20-20N/A1
12/31/2025N/A-12-13-103
12/31/2024N/A-9-8-83
6/30/2024N/A-7-8-8N/A
3/31/2024N/A-8-8-8N/A
12/31/2023N/A-8-8-8N/A
9/30/2023N/A-10-8-8N/A
6/30/2023N/A-10-9-9N/A
3/31/2023N/A-11-9-9N/A
12/31/2022N/A-11-9-9N/A
9/30/2022N/A-11-11-11N/A
6/30/2022N/A-12-11-11N/A
3/31/2022N/A-13-12-12N/A
12/31/2021N/A-14-12-12N/A
9/30/2021N/A-12-9-9N/A
6/30/2021N/A-10-8-8N/A
3/31/2021N/A-10-7-7N/A
12/31/2020N/A-7-6-6N/A
9/30/2020N/A-10-7-7N/A
6/30/2020N/A-10-7-7N/A
3/31/2020N/A-9-6-6N/A
12/31/2019N/A-8-5-5N/A
9/30/2019N/A-4-4-4N/A
6/30/2019N/A-3-3-3N/A
3/31/2019N/A-3-3-3N/A
12/31/2018N/A-2-2-2N/A
9/30/2018N/A-3-2-2N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: HOTH is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: HOTH is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: HOTH is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if HOTH's revenue is forecast to grow faster than the US market.

Yüksek Büyüme Geliri: HOTH is forecast to have no revenue next year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if HOTH's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin